These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 10407588)
1. Successful induction therapy of natural killer/cytotoxic T-lymphocyte cells in the treatment of Langerhans' cell histiocytosis. Hirose M; Kuroda Y Int J Hematol; 1999 Jun; 69(4):272-3. PubMed ID: 10407588 [No Abstract] [Full Text] [Related]
2. Treatment of patients with Langerhans cell histiocytosis with vindesine. Hirose M; Ishimoto K; Ninomiya T; Kuroda Y J Pediatr Hematol Oncol; 1996 Nov; 18(4):421-2. PubMed ID: 8888759 [No Abstract] [Full Text] [Related]
5. [Langerhans' cell histiocytosis: various manifestations with the same histopathologic base]. Martínez Baylach J; Pardo García N; Torrent Español M; Moliner Calderón E; Anquela Sanz I; Cubells Rieró J An Esp Pediatr; 2002 Nov; 57(5):484-7. PubMed ID: 12467553 [TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099 [TBL] [Abstract][Full Text] [Related]
7. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751 [TBL] [Abstract][Full Text] [Related]
8. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo. Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016 [TBL] [Abstract][Full Text] [Related]